Nectar Lifesciences Ltd. · NSE:NECLIFE
Nectar Lifesciences — Investor Presentation (October 2024)
16 slides from Nectar Lifesciences's investor presentation, Oct 21, 2024
Slide 1: Nectar Lifesciences Ltd. Intimation of Presentation of Business
Nectar Lifesciences Ltd. Ref.: NLL/CS/2024- 418 October 21, 2024 1. National Stock Exchange of India Limited 2. BSE Limited Listing Department, Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, P J Towers, Dalal Street, Bandra (E), Mumbai 400 051 Mumbai 400 001 Symbol: NECLIFE
Slide 2: Nectar Lifesciences Limited: A Cephalosporin Company
Nectar Lifesciences LIMITED A Cephalosporin Company
Slide 3: Cephalosporin Global Landscape
Cephalosporin Global Landscape World Pharmaceutical Market: $1.2tn Antibiotics Market: $100bn (Gen I-V) Ceph Market: $21bn (Gen I-V) $16bn Nectar Lifesciences Addressable Market Note: All figures in US$
Slide 4: About the Company
ABOUT THE COMPANY
Slide 5: Geography & Locations
Geography & Locations Barotiwala Landmark Location Activity Dera Bassi Corporate Chandigarh Corporate Functions HQ Global • Marketing & BD Chandigarh • Finance & Accounting • Supply chain • Secretarial & Legal Unit 1 Derabassi, Punjab Oral & Sterile Cephalosporin APIs Unit 2 Derabassi, Oral & Steril
Slide 6: Our Strength
Our Strength Well equipped to scale and capture a larger market share Global Competitive Leader in oe Cephalospori High Barriers n API to Entry Products Established Relationships with Marquee Customers
Slide 7: State-of-the-art facilities with leading global capabilities
NLL has state-of-the-art facilities with leading globalcapabilities API Manufacturing Formulations Description Unit 1 Unit 2 Unit 6 • Predominantly caters to domestic and less regulated markets Activities • Caters to semi regulated and highly • Sterile and non sterile cephalosporins regulated market
Slide 8: Manufacturing Capacities API
7 Manufacturing Capacities API Derabassi Unit-1 & Unit-2 ( API ) Oral Cefixime Trihydrate Cefpodoxime Proxetil Cefuroxime Axetil (Amorphous ) Cefdinir Ceftibuten Sterile Ceftriaxone Sodium Sterile Cefotaxime Sodium Sterile Cefuroxime Sodium Sterile Ceftazidime for Injection Cefipime HCL + Arginine C
Slide 9: Unit 2
Slide 10: Nectar Lifesciences API Leadership
Nectar Lifesciences API Leadership Oral Cephalosporins Sterile Cephalosporins Cefuroxime Cefotaxime Ceftriaxone Cefixime Axetil Sodium Sodium Crystalline • NLL has leading global capacities in Cefixime, Cefuroxime Axetil Amorphous, Cefuroxime Axetil Crystalline, Cefuroxime Cefotaxime Sodium, and Cef
Slide 11: API Manufacturing Unit and Global Approvals
Dice Oe Nedlife ~Y API Manufacturing Unit Two units with total of 120 Acre Land cover consisting over 13 manufacturing facilties with combination of 3 Sterile and 1 Oral API Blocks in First unit and 2 Sterile and 7 Oral API Blocks in second Unit Plant has total combined Oral-Sterile capacity of 1300
Slide 12: Unit 6 Formulation Unit
Unit 6 Formulation Unit i.
Slide 13: Finished Dosage Facility
Doane Pe FINISHED DOSAGE FACILITY |: MefVtes eR rere and PORTUGAL Poisons Board UU) infarmed Autoridade Nacional do Medicamento e Produtos de Saude LLP. . tpae Tanzania Medicines & Medical Devices Authority Safe Drugs Save Lives ae =r ANVISA 'e) OGYEI \e Orszagos Gydgyszerészeti és Elelmezés-egészsé
Slide 14: Statement of Financial Results for the Quarter ended 30.06.2024
Statement of Financial Results for the Quarter ended 30.06.2024 (Rs in Lacs) S. ]Particulars Standalone No. Quarter Ended Year Ended 30-Jun-24 | 31-Mar-24 | 30-Jun-23 31-Mar-24 Unaudited | Audited | Unaudited | Audited 1 [Income from Operations Sales 41,750.91 51,168.41 45,100.27 1,92,583.19 Less: G
Slide 15: Nectar Lifescience's Global Reach
Nectar Lifescience’s Global Reach Europe Belarus Russia Bulgaria Slovakia Hungary Spain Kazakhstan Turkey Romania Ukraine New Markets Japan, Korea, China Latin America Brazil Ecuador Cambodia Mexico Colombia Venezuela Asia Pacific Afghanistan Nepal Bangladesh Pakistan Africa & Middle-East Cambodia P
Slide 16: Thank You
THANK YOU |
Nectar Lifesciences — Investor Presentation (October 2024) on 6ix